Poignard P - Search Results

1

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.

Parren PW, Gauduin MC, Koup RA, Poignard P, Fisicaro P, Burton DR, Sattentau QJ. Parren PW, et al. Among authors: poignard p. Immunol Lett. 1997 Jun 1;57(1-3):105-12. doi: 10.1016/s0165-2478(97)00043-6. Immunol Lett. 1997. Corrected and republished in: Immunol Lett. 1997 Jul;58(2):125-32. doi: 10.1016/s0165-2478(97)00109-0. PMID: 9232434 Corrected and republished. Review.

2

Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.

Sattentau QJ, Zolla-Pazner S, Poignard P. Sattentau QJ, et al. Among authors: poignard p. Virology. 1995 Jan 10;206(1):713-7. doi: 10.1016/s0042-6822(95)80094-8. Virology. 1995. PMID: 7530400 Free article.

3

Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.

Sattentau QJ, Moore JP, Vignaux F, Traincard F, Poignard P. Sattentau QJ, et al. Among authors: poignard p. J Virol. 1993 Dec;67(12):7383-93. doi: 10.1128/JVI.67.12.7383-7393.1993. J Virol. 1993. PMID: 7693970 Free PMC article.

4

Human and simian immunodeficiency viruses: virus-receptor interactions.

Signoret N, Poignard P, Blanc D, Sattentau QJ. Signoret N, et al. Among authors: poignard p. Trends Microbiol. 1993 Dec;1(9):328-33. doi: 10.1016/0966-842x(93)90072-y. Trends Microbiol. 1993. PMID: 8162421 Review.

5

Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.

Poignard P, Fouts T, Naniche D, Moore JP, Sattentau QJ. Poignard P, et al. J Exp Med. 1996 Feb 1;183(2):473-84. doi: 10.1084/jem.183.2.473. J Exp Med. 1996. PMID: 8627160 Free PMC article.

6

Antibody neutralization of HIV-1.

Poignard P, Klasse PJ, Sattentau QJ. Poignard P, et al. Immunol Today. 1996 May;17(5):239-46. doi: 10.1016/0167-5699(96)10007-4. Immunol Today. 1996. PMID: 8991386 Review.

7

Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".

Parren PW, Gauduin MC, Koup RA, Poignard P, Sattentau QJ, Fisicaro P, Burton DR. Parren PW, et al. Among authors: poignard p. Immunol Lett. 1997 Jul;58(2):125-32. doi: 10.1016/s0165-2478(97)00109-0. Immunol Lett. 1997. PMID: 9271324 Review.

8

Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.

Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM, Burton DR. Sakurai H, et al. Among authors: poignard p. J Virol. 1999 Apr;73(4):2956-62. doi: 10.1128/JVI.73.4.2956-2962.1999. J Virol. 1999. PMID: 10074145 Free PMC article.

9

Antibody neutralization of HIV-1 and the potential for vaccine design.

Sattentau QJ, Moulard M, Brivet B, Botto F, Guillemot JC, Mondor I, Poignard P, Ugolini S. Sattentau QJ, et al. Among authors: poignard p. Immunol Lett. 1999 Mar;66(1-3):143-9. doi: 10.1016/s0165-2478(98)00174-6. Immunol Lett. 1999. PMID: 10203047 Review.

10

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, Parren PW, Mosier DE, Burton DR. Poignard P, et al. Immunity. 1999 Apr;10(4):431-8. doi: 10.1016/s1074-7613(00)80043-6. Immunity. 1999. PMID: 10229186 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters